Immunovaccine Announces Results of 2014 Annual General Meeting
April 24 2014 - 8:05AM
Marketwired
Immunovaccine Announces Results of 2014 Annual General Meeting
HALIFAX, NOVA SCOTIA--(Marketwired - Apr 24, 2014) -
Immunovaccine Inc. ("Immunovaccine" or "IMV") (TSX-VENTURE:IMV), a
clinical stage vaccine company, today announced the results of the
Company's Annual General Meeting (AGM) of shareholders held on
April 23, 2014.
During the AGM, the shareholders re-elected James W. Hall, Llew
Keltner, Ph.D., Stephanie Léouzon, Marc Mansour, Ph.D., Wayne
Pisano, Bradley Thompson, Ph.D., and Albert Scardino to serve on
the board of directors until the next annual meeting of
shareholders. Mr. Scardino will also continue his duties as
executive chairman of the board. Wade K. Dawe retired from the
board after nine years as a director.
"The Board and management wish to thank Wade for his service and
contributions to the Board," said Mr. Scardino.
Additionally, Kimberly Stephens, Immunovaccine's Chief Financial
Officer, has been re-appointed Corporate Secretary.
The shareholders approved all motions put forth at the meeting
including the appointment of PricewaterhouseCoopers LLP, Chartered
Accountants, as the Company's independent auditors.
About Immunovaccine
Immunovaccine Inc. develops cancer immunotherapies and
infectious disease vaccines based on the Company's DepoVax™
platform, a patented formulation that provides controlled and
prolonged exposure of antigens and adjuvants to the immune system.
Immunovaccine has advanced two T cell activation therapies for
cancer through Phase I human clinical trials. Lead cancer vaccine
therapy, DPX-Survivac, is expected to enter Phase II clinical
studies in 2014, in ovarian cancer and glioblastoma (brain cancer).
The Company is also advancing an infectious disease pipeline
including innovative vaccines for respiratory syncytial virus (RSV)
and anthrax.
Connect at: www.imvaccine.com
This press release contains forward-looking information
under applicable securities law. All information that addresses
activities or developments that we expect to occur in the future,
is forward-looking information. Forward-looking statements are
based on the estimates and opinions of management on the date the
statements are made. However, they should not be regarded as a
representation that any of the plans will be achieved. Actual
results may differ materially from those set forth in this press
release due to risks affecting the company, including access to
capital, the successful completion of clinical trials and receipt
of all regulatory approvals. Immunovaccine Inc. assumes no
responsibility to update forward-looking statements in this press
release except as required by law.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Immunovaccine Inc.Kimberly StephensCFO(902)
492-1819info@imvaccine.comwww.imvaccine.comVida Strategic Partners
(media)Tim Brons(415) 675-7402tbrons@vidasp.com